BACIL PHARMA Q2 : CONS NET LOSS AT ₹8.83 L FOR H1, REVENUE DOWN 82.9% YOY

• H1 revenue at ₹18.09 L v ₹105.74 L (YOY); Q2 revenue ₹9.18 L, up 3.0% (QOQ) from ₹8.91 L. • Profit before tax at ₹3.65 L for H1; net loss after tax at ₹8.83 L on deferred tax of ₹12.48 L. • Profit for the period including other comprehensive income at ₹39.18 L for H1. • Consolidated borrowings at ₹552.24 L as at Sep 30, 2026 v nil as at Mar 31, 2026; cash and equivalents at ₹97.41 L v ₹56.85 L.

Bacil Pharma Ltd

Open attachment

← Back to feed